Concretely: retatrutide · three days.
Everything I have found on this is either a forum aside or a product page, neither of which I trust.
I am comfortable with the arithmetic; what I am missing is the procedural detail around it.
What would you do, and what would you check afterwards?
3 days past a due dose is 0.43 half-lives at the seven-day half-life this class runs on, which leaves about 74.3 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(3÷7) = 0.743. At 74.3 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 10 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
The honest answer is that a single missed weekly dose is not an event, and that two in a row starts to matter.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
The underlying point is that to change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
Repeated missed doses are a different problem from an occasional one and should be treated as such.
Set a recurring reminder attached to something you already do weekly.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsIt helps to be literal here: this is one of the questions where the pharmacokinetics gives a reassuring answer and the anxiety persists anyway.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
To move your dosing day, move it later and keep three days between doses.
Start with the interval since the missed dose, because that single number determines the answer.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
Two or more missed weekly doses means considering a lower restarting step.
edited 11 Sept 2024 by h_villanueva — added the method parameters
Changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Answering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Never double up. Peak exposure is what drives the symptoms.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.